A Study to Evaluate MWN109 Tablets in Healthy Adult Participants
Status:
NOT_YET_RECRUITING
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered MWN109 tablets will be assessed in healthy adult participants.